Combining cell-free DNA fragmentomes and total tumour volume improves prognostication and tumour response evaluation in patients with colorectal cancer liver metastases.
Saved in:
| Title: | Combining cell-free DNA fragmentomes and total tumour volume improves prognostication and tumour response evaluation in patients with colorectal cancer liver metastases. |
|---|---|
| Authors: | Crnovrsanin N; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of General, Abdominal and Transplantation Surgery, University Hospital Heidelberg, Heidelberg, Germany., Zeeuw JM; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands., Ali M; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands., Kemna R; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands., Alipanahi B; Delfi Diagnostics, Inc., Baltimore, MD, USA., Lumbard K; Delfi Diagnostics, Inc., Baltimore, MD, USA., Skidmore ZL; Delfi Diagnostics, Inc., Baltimore, MD, USA., Rinaldi L; Delfi Diagnostics, Inc., Baltimore, MD, USA., van 't Erve I; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Wesdorp NJ; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands., Huiskens J; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., van Steijn D; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van Waesberghe JH; Cancer Center Amsterdam, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., van den Bergh J; Cancer Center Amsterdam, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Nota I; Cancer Center Amsterdam, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Moos S; Cancer Center Amsterdam, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands., Bond MJG; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands., Meiqari L; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Huitink I; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Giovannetti E; Cancer Center Amsterdam, Amsterdam, the Netherlands., Stoker J; Cancer Center Amsterdam, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Verpalen I; Cancer Center Amsterdam, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., van den Broek D; Department of Laboratory Medicine, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Meijer GA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Swijnenburg RJ; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands., Punt CJA; Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands., Scharpf RB; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Leal A; Delfi Diagnostics, Inc., Baltimore, MD, USA., Dracopoli NC; Delfi Diagnostics, Inc., Baltimore, MD, USA., Velculescu VE; The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Kok NFM; Department of Surgery, Netherlands Cancer Institute, Amsterdam, the Netherlands., Kazemier G; Department of Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands. Electronic address: g.kazemier@amsterdamumc.nl., Fijneman RJA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: r.fijneman@nki.nl. |
| Source: | EBioMedicine [EBioMedicine] 2026 Jan; Vol. 123, pp. 106081. Date of Electronic Publication: 2025 Dec 16. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101647039 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2352-3964 (Electronic) Linking ISSN: 23523964 NLM ISO Abbreviation: EBioMedicine Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
